Boston Scientific

Boston Scientific to present late-breaking data at the 2024 North American Neuromodulation Society (NANS) Meeting

MARLBOROUGH, Mass., Jan. 11, 2024 -- Boston Scientific Corporation (NYSE: BSX) today announced the company's clinical data that will be featured at the 27th North American Neuromodulation Society (NANS) annual meeting, to be held in Las Vegas, Nevada, on Jan.18-21, 2024. A total of 19 abstracts from its chronic pain and deep brain stimulation portfolios have been accepted, including a late-breaking presentation on the WaveWriter Alpha™ Spinal Cord Stimulation (SCS) System.

The SOLIS (SCS as an Option for Chronic Low Back and/or Leg Pain Instead of Surgery) randomized control trial, is evaluating the use of the WaveWriter SCS Systems for the treatment of non-surgical back pain (NSBP) when compared to conventional medical management (CMM). This late breaking presentation will review one-year outcomes of the trial.

"Boston Scientific is advancing the treatment paradigms for people living with chronic pain or movement disorders," said Jim Cassidy, president, Neuromodulation, Boston Scientific. "Data included at this year's NANS meeting reflect the breadth and depth of meaningful clinical evidence supporting our technologies and our commitment to deliver innovative solutions for physicians and their patients."

Additional data being presented on the Boston Scientific portfolio include clinical outcomes on Fast-Acting Sub-Perception Therapy (FAST) with SCS, and essential tremor real-world outcomes using Deep Brain Stimulation (DBS). Long-term outcomes on SCS for diabetic peripheral neuropathy (DPN) that support the most recent indication expansion for DPN will also be presented.

Featured Abstracts

Oral presentations:

- **RELIEF Diabetic Peripheral Neuropathy Long-term Outcomes:** Global, multicenter study of prospectively-enrolled patients utilizing SCS for painful-diabetic peripheral neuropathy to be presented by Anthony Berg, M.D., on Friday, Jan. 19 from 5:18-5:26 p.m. PT
- **Tremor Reduction Using Deep Brain Stimulation:** Outcomes of a real-world, prospective, multicenter essential tremor study to be presented by Jan Vesper, M.D., Ph.D., on Saturday, Jan. 20 from 10:48-10:56 a.m. PT
- **Clinical Outcomes Using Fast-Acting Sub-Perception-Based SCS:** Clinical outcomes using FAST-SCS results of a multicenter, observational real-world study in the United States to be presented by James North, M.D., on Saturday, Jan. 20 from 11:41-11:49 a.m. PT
- **SOLIS Randomized Control Trial:** Evaluating SCS and CMM for chronic pain without prior back surgery to be presented by James North, M.D., on Saturday, Jan. 20 from 2:07-2:15 p.m. PT

For a complete list of Boston Scientific clinical and scientific data presentations at NANS 2024, please visit: BostonScientific.com/NANS2024.

About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. For more information, visit **www.bostonscientific.com** and connect on **Twitter** and **LinkedIn**.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, product performance and impact, and clinical trials. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those

contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by extreme weather or other climate change-related events; labor shortages and increases in labor costs; new product introductions; expected procedural volumes; demographic trends; the closing and integration of acquisitions; intellectual property rights; litigation; financial market conditions; the execution and effect of our business strategy, including cost savings and growth initiatives; future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC"), which we may update in Part II, Item 1A – *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this press release.

CONTACTS:

Media:
Lisa Ferrer
+1.805.561.4075
lisa.ferrer@bsci.com

Investor Relations:
Lauren Tengler
+1.508.683.4479
lauren.tengler@bsci.com

---

https://news.bostonscientific.com/to-present-late-breaking-data-2024-North-American-Neuromodulation-Society